公开(公告)号：EP3851110A1

公开(公告)日：2021-07-21

申请号：EP20204879.9

申请日：2016-05-27

申请人： Kite Pharma, Inc. ,  The Government of the United States of America as represented by the Secretary, Department of Health and Human Services

发明人： BOT, Adrian ,  GO, William ,  JAIN, Rajul ,  WIEZOREK, Jeffrey S. ,  KOCHENDERFER, James N. ,  ROSENBERG, Steven A.

IPC分类号： A61K31/7076 ,  A61K31/675 ,  A61P35/02

摘要： The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

公开(公告)号：EP4249075A3

公开(公告)日：2023-11-08

申请号：EP23186520.5

申请日：2020-05-03

申请人： Kite Pharma, Inc.

发明人： JAIN, Rajul ,  VEZAN, Remus

IPC分类号： A61K31/573 ,  A61K38/34 ,  A61K35/17 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/454 ,  A61K31/675 ,  A61K31/704 ,  A61K38/18 ,  A61K38/19 ,  A61K39/00 ,  A61P1/00 ,  C07K14/725 ,  C07K16/06 ,  C07K16/24 ,  C07K16/28 ,  A61K31/7076 ,  A61K45/06 ,  A61P35/02

摘要： The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

公开(公告)号：EP3962490A1

公开(公告)日：2022-03-09

申请号：EP20801592.5

申请日：2020-05-03

申请人： Kite Pharma, Inc.

发明人： JAIN, Rajul ,  VEZAN, Remus

IPC分类号： A61K31/573 ,  A61K38/34 ,  A61K35/17

公开(公告)号：EP3302507A1

公开(公告)日：2018-04-11

申请号：EP16800846.4

申请日：2016-05-27

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  Kite Pharma, Inc.

发明人： BOT, Adrian ,  WIEZOREK, Jeffrey S. ,  GO, William ,  JAIN, Rajul ,  KOCHENDERFER, James N. ,  ROSENBERG, Steven A.

IPC分类号： A61K35/17 ,  A61K38/20 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/19 ,  C12N15/24

CPC分类号： A61K35/17 ,  A61K31/095 ,  A61K31/445 ,  A61K31/52 ,  A61K31/665 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00 ,  C07K14/00 ,  C07K14/52 ,  C12N5/0636 ,  C12N15/00 ,  C12N15/85 ,  C12N2510/00 ,  G01N33/6869 ,  G01N2333/5418 ,  G01N2333/5443

摘要： The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

公开(公告)号：EP4249075A2

公开(公告)日：2023-09-27

申请号：EP23186520.5

申请日：2020-05-03

申请人： Kite Pharma, Inc.

发明人： JAIN, Rajul ,  VEZAN, Remus

IPC分类号： A61P35/02

摘要： The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

公开(公告)号：EP3302508A1

公开(公告)日：2018-04-11

申请号：EP16800847.2

申请日：2016-05-27

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  Kite Pharma, Inc.

发明人： BOT, Adrian ,  WIEZOREK, Jeffrey ,  JAIN, Rajul ,  KOCHENDERFER, James ,  ROSENBERG, Steven

IPC分类号： A61K35/26 ,  C12N5/0783 ,  C12N5/0784

CPC分类号： A61K35/17 ,  A61K31/664 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/2013 ,  A61K38/2053 ,  A61K45/06 ,  A61P35/02 ,  A61K2300/00

摘要： The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.